If you need help accessing our website, call 855-698-9991
NYU Langone Provider

Qandeel H. Soomro, MD

NYU Langone Provider
  • Specialty: Nephrology
  • Treats: Adults
  • Language: English

During medical school I became intrigued by human physiology and how different systems in the body work. This fascination led me to become a nephrologist at NYU Langone, specializing in treating kidney conditions. I help patients with complex, critical illnesses—acute kidney conditions, chronic kidney diseases, and hypertensive disorders. In addition, I help individuals with end-stage kidney disease who require dialysis.

I strongly believe in taking a holistic approach to patient care, treating people with compassion and understanding while guiding them through the complexities of kidney disease. I enjoy getting to know my patients and what is important to them, so we can come up with a treatment plan that works for them.

In addition to my clinical work, I’m actively involved in research. I’ve dedicated my research to the intersection of heart health and the body’s internal control systems—autonomic dysfunction—as part of chronic kidney disease (CKD). I’m interested in understanding how kidney disease affects heart health and vice versa, especially during dialysis, and how our body’s adaptive reflexes can influence this.

I am proud that my contributions to the field have been recognized through the American Society of Nephrology Donald E. Wesson Fellowship Grant. This honor supported my research into the links between certain heart measurements (electrocardiographic parameters) and the risk of heart failure among individuals with CKD. The grant also allowed me to develop models that can help us identify people at high risk of heart failure at an early stage.

My ultimate goal is to turn these research findings into real-world solutions. I want to improve the lives of people dealing with chronic kidney disease and make their journey a little easier and their future a little brighter.


Conditions and Treatments

Conditions
  • acute renal failure
  • chronic renal failure
  • electrolyte imbalance
  • glomerular disease
  • kidney disease

Board Certifications
  • American Board of Internal Medicine (Nephrology), 2021
  • American Board of Internal Medicine - Internal Medicine, 2014
Education and Training
  • Fellowship, New York University School of Medicine, Nephrology, 2021
  • Residency, University of Missouri-Kansas City School of Medicine, Internal Medicine, 2014
  • MD from Dow Medical College, 2009

Is this your profile?

Edit profile

This provider accepts the following insurance plans.

View All Accepted Plans This list of insurances changes regularly, and insurance plans listed may not be accepted at all office locations for this provider. Before your appointment, please confirm with your insurance company that this provider accepts your insurance.

Qandeel H. Soomro, MD does not accept insurance.

Interests

kidney disease

Research Summary

As a physician-scientist, my research centers on the convergence of cardiovascular health and autonomic dysfunction within chronic kidney disease (CKD). My primary focus involves bridging knowledge gaps and advancing treatments for cardiovascular complications in CKD, particularly exploring the impact of dialysis on cardiovascular function and understanding the pivotal role of autonomic physiology in CKD-related cardiovascular complications.

My contributions include being honored with the American Society of Nephrology Donald E. Wesson Fellowship grant. This prestigious grant supported my investigation into the correlations between electrocardiographic parameters and the risk of heart failure among individuals with CKD. Moreover, it allowed the development of predictive models for the early identification of high-risk individuals.

My ultimate objective is to translate these research findings into tangible solutions that improve the lives of individuals grappling with chronic kidney disease.

  • A Single Center Pilot Study on the Use of a Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population

    Learn More
  • A phase II randomized double-blind placebo-controlled multi-center study to assess the safety tolerability and preliminary efficacy of empagliflozin among patients with residual kidney function receiving hemodialysis for the treatment of end-stage kidney disease

    Learn More
  • Intradialytic Myocardial Study Stunning in Maintenance Hemodialysis Patients: A Multi-Center Observational Cohort Study

    Learn More
View All Research Studies (3)

Read All Publications (24)